All agree that good patient adherence to their treatment regime is critical. However, a number of patients decide not to take their medicines as directed. The direct and consequential cost and health impacts of poor patient adherence are considerable, but changing behaviour is proving a challenge. For deep background research and critical insights to tackle this issue turn to this new report. Learn more.
AbbVie announced Friday that the FDA granted priority review for the company's experimental two direct-acting antiviral therapy consisting of ombitasvir, paritaprevir, and ritonavir, with ribavirin,... Read More >>